<p>CRISPR Therapeutics (CRSP) 最近宣布了其体内心血管疾病项目的重要进展，特别是 CTX310 和 CTX320，这可能是公司在上个季度股价上涨 47% 的原因之一。公司被纳入多个指数进一步增强了其市场存在感，可能对投资者的兴趣产生积极影响。与此同时，CRISPR 在第一季度的财报中报告了净亏损，尽管收入同比增长。尽管市场背景波动，主要指数因疲弱的就业报告和关税担忧而下跌，但 CRISPR 在治疗项目的进展和战略性指数的增加与更广泛的市场走势形成了对比。</p>
<p>我们发现了一个您需要注意的 CRISPR Therapeutics 风险。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b662408d-9ba7-4c0f-acf0-36bda091061a/chart/earnings-per-share-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b662408d-9ba7-4c0f-acf0-36bda091061a/chart/earnings-per-share-growth"/></p>
<p>截至 2025 年 8 月的 CRSP 每股收益增长</p>
<p>通过财务稳健的低价股发现下一个大机会，这些股票在风险和回报之间取得平衡。</p>
<p>在过去一年中，CRISPR Therapeutics 报告的股东总回报为 9.74%。虽然公司的股票表现优于美国生物技术行业，该行业在同一时期的回报下降了 8.4%，但仍落后于更广泛的美国市场 17.7% 的回报。相对于其行业的良好表现可以归因于其在心血管疾病项目的战略进展和被纳入多个罗素指数。</p>
<p>引言中强调的最新进展，特别是 CRISPR 在心血管项目和指数增加方面的积极更新，可能会影响对未来收入和收益的预期。分析师预测年均强劲的收入增长为 57.3%，尽管公司预计在未来三年内仍将处于亏损状态。与此同时，当前股价为 56.09 美元，市场似乎低估了分析师共识目标价 80.91 美元，反映出该股票的潜在上涨空间。这一价格走势表明，投资者可能会看到潜在的增长机会，即使公司在盈利能力方面面临挑战。</p>
<p>我们编制的估值报告表明，CRISPR Therapeutics 当前的价格可能相当适中。</p>
<p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>

CRISPR治疗

<p>CRISPR Therapeutics (CRSP) 在过去一个季度的股价上涨了 47%，这得益于其心血管疾病项目的进展以及被纳入多个指数。尽管在第一季度报告了净亏损，但收入同比增长。该公司过去一年的总股东回报率为 9.74%，超过了美国生物技术行业的表现。分析师预测年收入增长将达到 57.3%，尽管预计 CRISPR 在未来三年内将继续亏损。目前的股价为 56.09 美元，相较于分析师的目标价 80.91 美元，显示出显著的上涨潜力</p>

<p>CRISPR Therapeutics (CRSP) recently announced significant developments in its in vivo cardiovascular disease programs, notably CTX310 and CTX320, which may have contributed to the company's 47% share price increase over the last quarter. The company's inclusion in multiple indices further enhances its market presence, potentially impacting investor interest positively. Meanwhile, CRISPR reported a net loss in its Q1 earnings, although revenue increased year-over-year. Despite a volatile market backdrop, characterized by declining major indices due to weak job reports and tariff concerns, CRISPR's advancements in therapeutic programs and strategic index additions contrasted against broader market movements.</p>
<div class="lb-trans"><p>CRISPR Therapeutics (CRSP) 最近宣布了其体内心血管疾病项目的重要进展，特别是 CTX310 和 CTX320，这可能是公司在上个季度股价上涨 47% 的原因之一。公司被纳入多个指数进一步增强了其市场存在感，可能对投资者的兴趣产生积极影响。与此同时，CRISPR 在第一季度的财报中报告了净亏损，尽管收入同比增长。尽管市场背景波动，主要指数因疲弱的就业报告和关税担忧而下跌，但 CRISPR 在治疗项目的进展和战略性指数的增加与更广泛的市场走势形成了对比。</p>
</div><p>We've spotted 1 risk for CRISPR Therapeutics you should be aware of.</p>
<div class="lb-trans"><p>我们发现了一个您需要注意的 CRISPR Therapeutics 风险。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b662408d-9ba7-4c0f-acf0-36bda091061a/chart/earnings-per-share-growth" alt="" original-src="https://images.simplywall.st/company/b662408d-9ba7-4c0f-acf0-36bda091061a/chart/earnings-per-share-growth"/></p>
<p>CRSP Earnings Per Share Growth as at Aug 2025</p>
<div class="lb-trans"><p>截至 2025 年 8 月的 CRSP 每股收益增长</p>
</div><p>Uncover the next big thing with financially sound penny stocks that balance risk and reward.</p>
<div class="lb-trans"><p>通过财务稳健的低价股发现下一个大机会，这些股票在风险和回报之间取得平衡。</p>
</div><p>Over the past year, CRISPR Therapeutics reported a total shareholder return of 9.74%. While the company's shares outperformed the US Biotechs industry, which returned a decline of 8.4% over the same period, it lagged behind the broader US Market's 17.7% return. The favorable performance relative to its industry can be linked to its strategic advancements in cardiovascular disease programs and inclusion in various Russell indices.</p>
<div class="lb-trans"><p>在过去一年中，CRISPR Therapeutics 报告的股东总回报为 9.74%。虽然公司的股票表现优于美国生物技术行业，该行业在同一时期的回报下降了 8.4%，但仍落后于更广泛的美国市场 17.7% 的回报。相对于其行业的良好表现可以归因于其在心血管疾病项目的战略进展和被纳入多个罗素指数。</p>
</div><p>The recent developments highlighted in the introduction, particularly the positive updates in CRISPR's cardiovascular programs and index additions, could potentially influence expectations around future revenue and earnings. Analysts forecast strong revenue growth of 57.3% annually, despite the company's forecast to remain unprofitable over the next three years. Meanwhile, with the current share price at $56.09, the market seems to discount the consensus analyst price target of $80.91, reflecting a substantial perceived upside potential in the stock. This price movement suggests that investors might see potential growth opportunities, even as the company navigates its profitability challenges.</p>
<div class="lb-trans"><p>引言中强调的最新进展，特别是 CRISPR 在心血管项目和指数增加方面的积极更新，可能会影响对未来收入和收益的预期。分析师预测年均强劲的收入增长为 57.3%，尽管公司预计在未来三年内仍将处于亏损状态。与此同时，当前股价为 56.09 美元，市场似乎低估了分析师共识目标价 80.91 美元，反映出该股票的潜在上涨空间。这一价格走势表明，投资者可能会看到潜在的增长机会，即使公司在盈利能力方面面临挑战。</p>
</div><p>The valuation report we've compiled suggests that CRISPR Therapeutics' current price could be quite moderate.</p>
<div class="lb-trans"><p>我们编制的估值报告表明，CRISPR Therapeutics 当前的价格可能相当适中。</p>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>
</div>

CRISPR Therapeutics (CRSP) 在过去一个季度中价格上涨了 47%